| Literature DB >> 20569687 |
Alan Trounson1, Elona Baum, Don Gibbons, Patricia Tekamp-Olson.
Abstract
Cell therapies derived from pluripotent stem cells are entering the preclinical and early clinical development phase, but eventual translation faces many challenges. We describe a new approach by California to form global public-private "disease team" partnerships to enable new clinical opportunities to be evaluated in the complex regulatory environment. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Year: 2010 PMID： 20569687 DOI： 10.1016/j.stem.2010.05.008
Source DB: PubMed Journal: Cell Stem Cell ISSN： 1875-9777 Impact factor: 24.633